CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS

Various immune cells as well as related cytokines are involved in immunopathogenesis of sarcoidosis and mechanisms of granuloma development. Currently, a role for chemokines in sarcoidosis has been extensively investigated, which is paralleled with a search for key molecules necessary for recruiting...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N. M. Lazareva, O. P. Baranova, I. V. Kudryavtsev, D. V. Isakov, N. A. Arsentieva, N. E. Liubimova, T. P. Ses’, M. M. Ilkovich, A. A. Totolian
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	sarcoidosis chemokines ccl17 ccl22 peripheral blood plasma Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1210bec412154f91a2e318934f66fd7d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1210bec412154f91a2e318934f66fd7d
record_format	dspace
spelling	oai:doaj.org-article:1210bec412154f91a2e318934f66fd7d2021-11-18T08:03:51ZCHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS1563-06252313-741X10.15789/1563-0625-CCA-2340https://doaj.org/article/1210bec412154f91a2e318934f66fd7d2021-10-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2340https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XVarious immune cells as well as related cytokines are involved in immunopathogenesis of sarcoidosis and mechanisms of granuloma development. Currently, a role for chemokines in sarcoidosis has been extensively investigated, which is paralleled with a search for key molecules necessary for recruiting immune cells to intrusion site and granuloma formation as well as affecting outcome of the latter. Our study was aimed for determining level of plasma CCL17/TARC and CCL22/MDC chemokines in patients with sarcoidosis who received no immunosuppressive therapy is of high priority for clarifying some aspects in underlying immunopathogenesis as well as seeking out for secure clinical and laboratory criteria for assessing activity and disease prognosis. We studied peripheral blood plasma samples of the patients with sarcoidosis (n = 52). In 37% (19/52), they exhibited acute clinical manifestations, and 63% (33/52) had chronic sarcoidosis. The control group included peripheral blood samples from healthy volunteers (n = 22). The chemokine concentrations (pg/ml) were determined by multiplex analysis using xMAP technology (Luminex), and Milliplex MAP test system (Millipore, USA). In the patients with sarcoidosis, significantly higher levels of chemokines were shown relative to healthy volunteers: CCL17 – 78.24 pg/ml vs 26.24 pg/ml, p < 0.001; CCL22 – 660.60 pg/ml vs 405.00 pg/ml, p < 0.001. Evaluation of clinical and laboratory diagnostic characteristics for plasma chemokine levels in sarcoidosis patients allowed to assess their sensitivity and specificity. The respective values were as follows: in acute sarcoidosis: for CCL17 – 63% and 78%, CCL22 – 63% and 91%; in chronic sarcoidosis: CCL17 – 58% and 83%, CCL22 – 67% and 86%, respectively. In chronic sarcoidosis the levels of this chemokine correlated with the activity of angiotensin-converting enzyme (ACE), for CCL17 (r = 0.530; p = 0.003), for CCL22 (r = 0.446; p = 0.014). Patients with systemic lesions vs no systemic lesions (sarcoidosis of the respiratory system only) had significantly elevated CCL17 level: 102.82 pg/ml vs 32.72 pg/ml, p = 0.011. The concentration of chemokine CCL17 was significantly increased in patients with vs without signs of hepatomegaly: 130.73 pg/ml vs 51.60 pg/ml, p = 0.022. Levels of chemokines was significantly increased in patients with vs without ultrasound signs of splenomegaly comprising: for CCL17 – 249.18 pg/ml vs 46.87 pg/ml, p = 0.002; for CCL22 – 1271.40 pg/ml vs 660.63 pg/ml, p = 0.003. Thus, it should be noted that the peripheral blood plasma level of chemokines CCL17 and CCL22 may be used as additional prognostic markers in chronic sarcoidosis with varying scoring of clinical signs including with/without systemic disease manifestations.N. M. LazarevaO. P. BaranovaI. V. KudryavtsevD. V. IsakovN. A. ArsentievaN. E. LiubimovaT. P. Ses’M. M. IlkovichA. A. TotolianSPb RAACIarticlesarcoidosischemokinesccl17ccl22peripheral blood plasmaImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 4, Pp 791-798 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	sarcoidosis chemokines ccl17 ccl22 peripheral blood plasma Immunologic diseases. Allergy RC581-607
spellingShingle	sarcoidosis chemokines ccl17 ccl22 peripheral blood plasma Immunologic diseases. Allergy RC581-607 N. M. Lazareva O. P. Baranova I. V. Kudryavtsev D. V. Isakov N. A. Arsentieva N. E. Liubimova T. P. Ses’ M. M. Ilkovich A. A. Totolian CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
description	Various immune cells as well as related cytokines are involved in immunopathogenesis of sarcoidosis and mechanisms of granuloma development. Currently, a role for chemokines in sarcoidosis has been extensively investigated, which is paralleled with a search for key molecules necessary for recruiting immune cells to intrusion site and granuloma formation as well as affecting outcome of the latter. Our study was aimed for determining level of plasma CCL17/TARC and CCL22/MDC chemokines in patients with sarcoidosis who received no immunosuppressive therapy is of high priority for clarifying some aspects in underlying immunopathogenesis as well as seeking out for secure clinical and laboratory criteria for assessing activity and disease prognosis. We studied peripheral blood plasma samples of the patients with sarcoidosis (n = 52). In 37% (19/52), they exhibited acute clinical manifestations, and 63% (33/52) had chronic sarcoidosis. The control group included peripheral blood samples from healthy volunteers (n = 22). The chemokine concentrations (pg/ml) were determined by multiplex analysis using xMAP technology (Luminex), and Milliplex MAP test system (Millipore, USA). In the patients with sarcoidosis, significantly higher levels of chemokines were shown relative to healthy volunteers: CCL17 – 78.24 pg/ml vs 26.24 pg/ml, p < 0.001; CCL22 – 660.60 pg/ml vs 405.00 pg/ml, p < 0.001. Evaluation of clinical and laboratory diagnostic characteristics for plasma chemokine levels in sarcoidosis patients allowed to assess their sensitivity and specificity. The respective values were as follows: in acute sarcoidosis: for CCL17 – 63% and 78%, CCL22 – 63% and 91%; in chronic sarcoidosis: CCL17 – 58% and 83%, CCL22 – 67% and 86%, respectively. In chronic sarcoidosis the levels of this chemokine correlated with the activity of angiotensin-converting enzyme (ACE), for CCL17 (r = 0.530; p = 0.003), for CCL22 (r = 0.446; p = 0.014). Patients with systemic lesions vs no systemic lesions (sarcoidosis of the respiratory system only) had significantly elevated CCL17 level: 102.82 pg/ml vs 32.72 pg/ml, p = 0.011. The concentration of chemokine CCL17 was significantly increased in patients with vs without signs of hepatomegaly: 130.73 pg/ml vs 51.60 pg/ml, p = 0.022. Levels of chemokines was significantly increased in patients with vs without ultrasound signs of splenomegaly comprising: for CCL17 – 249.18 pg/ml vs 46.87 pg/ml, p = 0.002; for CCL22 – 1271.40 pg/ml vs 660.63 pg/ml, p = 0.003. Thus, it should be noted that the peripheral blood plasma level of chemokines CCL17 and CCL22 may be used as additional prognostic markers in chronic sarcoidosis with varying scoring of clinical signs including with/without systemic disease manifestations.
format	article
author	N. M. Lazareva O. P. Baranova I. V. Kudryavtsev D. V. Isakov N. A. Arsentieva N. E. Liubimova T. P. Ses’ M. M. Ilkovich A. A. Totolian
author_facet	N. M. Lazareva O. P. Baranova I. V. Kudryavtsev D. V. Isakov N. A. Arsentieva N. E. Liubimova T. P. Ses’ M. M. Ilkovich A. A. Totolian
author_sort	N. M. Lazareva
title	CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
title_short	CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
title_full	CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
title_fullStr	CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
title_full_unstemmed	CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS
title_sort	chemokines ccl17 and ccl22 in sarcoidosis
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/1210bec412154f91a2e318934f66fd7d
work_keys_str_mv	AT nmlazareva chemokinesccl17andccl22insarcoidosis AT opbaranova chemokinesccl17andccl22insarcoidosis AT ivkudryavtsev chemokinesccl17andccl22insarcoidosis AT dvisakov chemokinesccl17andccl22insarcoidosis AT naarsentieva chemokinesccl17andccl22insarcoidosis AT neliubimova chemokinesccl17andccl22insarcoidosis AT tpses chemokinesccl17andccl22insarcoidosis AT mmilkovich chemokinesccl17andccl22insarcoidosis AT aatotolian chemokinesccl17andccl22insarcoidosis
_version_	1718422273074921472

CHEMOKINES CCL17 AND CCL22 IN SARCOIDOSIS

Ejemplares similares